688658.SH
悦康药业
SSE · Healthcare · Biotechnology · CN
CNY 13.21
−7.69%Year over year
Reported trailing growth
- Revenue
- -28.5%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +318.7%
- Operating cash flow
- -18.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -18.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -15.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026